Objectives: No definitive risk factors for osteosarcoma have been identified. To assess regional differences, it is essential to minimize racial and other biases. However, few studies have examined this issue with minimal bias. This study aimed to evaluate regional variations in the incidence and characteristics of osteosarcoma in a rural prefecture with limited population mobility within ethnically homogeneous Japan. SubjectandMethods: We retrospectively identified 40 patients with primary osteosarcoma who received treatment at our hospital from 2000 to 2024. Clinical data were collected. Akita City, the prefectural capital and most populous city in Akita Prefecture, was compared with other cities, towns, villages, and regions regarding incidence and prognosis. We also examined poor prognostic factors across all cases. Results: The incidence rate in Area 2 was significantly higher than that in Area 1 (P = 0.0269). Across municipalities, Oga City in Area 2 and Yuzawa City in Area 5 exhibited significantly higher incidence rates than Akita City (P = 0.0243 and P = 0.0477). Kaplan-Meier analysis comparing the prognosis of Area 1 with Areas 2 and 5 showed that only Area 2 had a significantly worse prognosis than Area 1. Univariate analysis of prognostic factors demonstrated that surgical treatment was the sole factor associated with improved prognosis. Conclusion: These findings suggest the existence of regional differences in the incidence and characteristics of osteosarcoma.
References
[1]
Gelberg, K., Fitzgerald, E., Hwang, S. and Dubrow, R. (1997) Growth and Development and Other Risk Factors for Osteosarcoma in Children and Young Adults. InternationalJournalofEpidemiology, 26, 272-278. https://doi.org/10.1093/ije/26.2.272
[2]
Zhang, C., Morimoto, L.M., de Smith, A.J., Hansen, H.M., Gonzalez‐Maya, J., Endicott, A.A., et al. (2018) Genetic Determinants of Childhood and Adult Height Associated with Osteosarcoma Risk. Cancer, 124, 3742-3752. https://doi.org/10.1002/cncr.31645
[3]
Parkin, D.M., Stiller, C.A. and Nectoux, J. (1993) International Variations in the Incidence of Childhood Bone Tumours. InternationalJournalofCancer, 53, 371-376. https://doi.org/10.1002/ijc.2910530305
[4]
Katzman, S.S. and Johnston, J.O. (1991) Epidemiology of Primary Osteogenic Sarcoma in the San Francisco Bay Area of California. ClinicalOrthopaedicsandRelatedResearch, 263, 227-232. https://doi.org/10.1097/00003086-199102000-00028
[5]
Bovill, E.G. and Subramanian, N. (1975) An Epidemiologic Study of Osteogenic Sarcoma in Malaysia. ClinicalOrthopaedicsandRelatedResearch, 113, 119-127. https://doi.org/10.1097/00003086-197511000-00017
[6]
Hirano, T., Yoshida, G., Baba, H., Iwasaki, K., Kumashiro, T. and Soda, M. (1995) Incidence of Osteosarcoma in Nagasaki. Seikeigeka to Saigaigeka, 44, 421-423. (In Japanese).
[7]
WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. WHO Classification of Tumours. 5th Edition, IARC Press.
[8]
Rosen, G., Caparros, B., Huvos, A.G., Kosloff, C., Nirenberg, A., Cacavio, A., et al. (1982) Preoperative Chemotherapy for Osteogenic Sarcoma: Selection of Postoperative Adjuvant Chemotherapy Based on the Response of the Primary Tumor to Preoperative Chemotherapy. Cancer, 49, 1221-1230. https://doi.org/10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e
[9]
Enneking, W.F., Spanier, S.S. and Goodman, M.A. (1980) A System for the Surgical Staging of Musculoskeletal Sarcoma. ClinicalOrthopaedicsandRelatedResearch, 153, 106-120. https://doi.org/10.1097/00003086-198011000-00013
[10]
Iwamoto, Y., Tanaka, K., Isu, K., Kawai, A., Tatezaki, S., Ishii, T., et al. (2009) Multiinstitutional Phase II Study of Neoadjuvant Chemotherapy for Osteosarcoma (NECO Study) in Japan: NECO-93J and Neco-95j. JournalofOrthopaedicScience, 14, 397-404. https://doi.org/10.1007/s00776-009-1347-6
[11]
Iwamoto, Y. and Tanaka, K. (2012) The Activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. JapaneseJournalofClinicalOncology, 42, 467-470. https://doi.org/10.1093/jjco/hys059
[12]
Karimi, A., Ebrahimpour, A., Sadighi, M., Chehrassan, M., Biglari, F., Jafari Kafia-badi, M., Akbari, M.E. and Azizmohammad Looha, M. (2023) Descriptive Epidemiology and Survival Rate of Osteosarcoma: The First National Population-Based Study in the Middle East (2008-2014). The Archives of Bone and Joint Surgery, 11, 649-657.
[13]
Sadykova, L.R., Ntekim, A.I., Muyangwa-Semenova, M., Rutland, C.S., Jeyapalan, J.N., Blatt, N., et al. (2020) Epidemiology and Risk Factors of Osteosarcoma. CancerInvestigation, 38, 259-269. https://doi.org/10.1080/07357907.2020.1768401
[14]
Hu, X., Fujiwara, T., Houdek, M.T., Chen, L., Huang, W., Sun, Z., et al. (2022) Impact of Racial Disparities and Insurance Status in Patients with Bone Sarcomas in the USA: A Population-Based Cohort Study. Bone&JointResearch, 11, 278-291. https://doi.org/10.1302/2046-3758.115.bjr-2021-0258.r2
[15]
Tsuchie, H., Emori, M., Nagasawa, H., Miyakoshi, N., Murahashi, Y., Shimizu, J., et al. (2019) Prognosis of Primary Osteosarcoma in Elderly Patients: A Comparison between Young and Elderly Patients. MedicalPrinciplesandPractice, 28, 425-431. https://doi.org/10.1159/000500404